A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety Tolerability, Pharmacokinetics, and Pharmacosymics of Single Ascending Doses of Intravenously Administerted ALTB-268 in Healthy Participants
Latest Information Update: 27 Jan 2026
At a glance
- Drugs Leiolizumab (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors AltruBio
Most Recent Events
- 27 Jan 2026 New trial record